Real-world Comparative Effectiveness of Rivaroxaban Versus VKA

Inclusion Criteria:

- NVAF(non-valvular atrial fibrillation) will be defined as the occurrence of 2 or more
inpatient or outpatient claims with ICD(International Classification of Disease)-9
427.31 as the diagnosis code at any time in the patient's data history prior to
inclusion

- Patients will be required to have 180 days of enrollment for the assessment of
baseline characteristics

- CHA2DS2-Vasc score ≥2 during the 180 days prior to index rivaroxaban use baseline
period (CHA2DS2-Vasc: Diabetes mellitus; S2: prior Stroke or TIA or Thromboembolism;
V: Vascular disease; A: Age 65-74 years; Sc: Sex category)

Exclusion Criteria:

- Patients <18 years of age

- Patients with valvular AF (Atrial fibrillation)

- Pregnancy

- Malignant cancers

- Transient cause of AF

- Patients with venous thromboembolism (pulmonary embolism or deep vein thrombosis)

- Patients with major surgery defined as hip or knee replacement

- Prescriptions of oral anticoagulants (OACs) (apixaban, warfarin, dabigatran,
rivaroxaban) before index date

- Prescription of more than one OAC on the index date

- Patient with any of the events defined in the composite endpoint

- Fatal bleeding

- Fatal Stroke/Myocardial infarction

- Intracranial hemorrhage

- Ischemic stroke

- Myocardial infarction